04.12.2024
The overall pharmaceutical market in Ukraine grew in monetary and physical terms during the first nine months of 2024. The retail segment experienced increased monetary volume, while physical volume remained nearly unchanged. Conversely, monetary volume remained stable in the hospital segment, whereas physical volume grew.
The public sector’s share of the overall consumption of medicines remains low. Despite the full-scale war that significantly impacted the pharmaceutical market, particularly the hospital segment, Ukraine’s procurement system for medical goods is showing progress. Centralized procurement programs under the Ministry of Health (MOH) of Ukraine are gradually transitioning to three-year planning, and managed entry agreements (MEAs) are being actively implemented.
This publication analyzes trends in the supply of medicines to healthcare institutions (HCIs) and the results of tender procurement during the first three quarters of 2024. The data is based on the analytical “PharmXplorer” system of the Market Audit Ukraine project by Proxima Research.
The hospital market analysis includes data on accepted tenders and proposals from Prozorro Market, signed “below-threshold” procurement contracts for medicines and medical devices, distributor shipments, and samples from HCIs. Calculations are based on monthly funding volumes from local and state budgets. The analysis covered around 10,000 stock-keeping units (SKUs) of medicines.
Proxima Research systematically monitors procurement data, including state MOH programs and transactions of privately owned medical institutions.
For the first nine months of 2024, the total retail and hospital consumption of medicines reached UAH 120.5 billion in monetary terms and 704.9 million packs in physical terms. The hospital segment accounted for 8.7% in monetary terms and 11.5% in physical terms.
The volume of medicine supplies to HCIs during the reporting period amounted to UAH 10.5 billion, with UAH 7.9 billion sourced from local and interdepartmental procurements and UAH 2.6 billion allocated through MOH programs. Additionally, private clinics received supplies worth UAH 946.1 million.
Compared to the same period in the previous year, the overall volume of hospital supplies remained unchanged in monetary terms but grew by 13.7% in physical terms.
Typically, the largest volumes of medicine supplies to HCIs occur towards the end of the year, meaning the results for 2024 will largely depend on the fourth quarter.
Leading brands in MOH centralized procurement during the reporting period included Elaprase (for treating rare genetic disorders), Feiba (a coagulation factor VIII inhibitor), and Ruxience (an antineoplastic agent).
For regional procurements, the most in-demand products were Sodium Chloride (a common infusion solution), Actilyse (a thrombolytic agent), and Bioven (used for immune deficiency therapy).
In private medical institutions, leading products included Gonal (a hormone therapy for infertility), Tomogexol (a diagnostic contrast agent), and Keytruda (an oncology treatment).
International companies dominate centralized MOH procurement and private sector supplies, whereas local manufacturers lead regional procurements.
Key marketing organizations supplying MOH programs include Takeda, Pfizer, and Sanofi, while Ukrainian companies Yuria-Pharm and Farmak are prominent in regional segments.
For the first nine months of 2024, 23,300 tenders for medicine procurement were accepted, totaling UAH 10.5 billion (excluding centralized MOH procurement). Compared to the same period in 2023, the number of accepted tenders in regional procurement grew by 20.2%, while procurement volumes increased by 30.8%. The highest procurement activity traditionally occurs early in the year.
On November 19, 2024, the Ukrainian Parliament passed the “State Budget of Ukraine for 2025” law. According to MOH, healthcare funding will amount to UAH 217 billion, with UAH 11.8 billion allocated for procuring medicines and medical devices.
Within the 2024–2026 strategy, the Medical Procurement of Ukraine (MPU) plans to transform into a medical supply agency, introducing three-year procurement planning. Under this approach, MOH determines the list and volumes of medicines, after which MPU begins procurement.
Initially, three-year contracts will focus on oncology medicines, with plans to expand this approach to other areas. This format allows suppliers to plan production and delivery schedules in advance, potentially reducing prices. However, Ukraine’s annual state budget approval process creates risks, as contracts will be based on unapproved budgets.
The MEA mechanism, implemented in 2022 for procuring innovative and high-cost medicines, continues to expand. Recently, the Cabinet of Ministers approved changes to enhance MEA efficiency, including plans by MOH to expand the list of medicines covered by this mechanism.
As of late 2024, MPU has signed 16 MEAs covering medicines for rare diseases, including:
This approach ensures that patients with rare diseases receive the necessary treatment, improving the efficiency of the national healthcare system.
A promotional strategy requires an omnichannel approach that coordinates different communication channels to ensure consistency and effectiveness of promotional impact on the audience.
By clicking«Submit», you consent to receive email communications about Proxima Research products and services and agree to our Terms of Use. Your data will be processed in accordance with our Privacy Police. You may opt-out at any time.
or
